Literature DB >> 20509777

Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.

Sylvia Deppe1, Rainer H Böger, Johanna Weiss, Ralf A Benndorf.   

Abstract

IMPORTANCE OF THE FIELD: Telmisartan belongs to the angiotensin II type 1 (AT1) receptor antagonizing class of antihypertensives, which are widely recognized and increasingly prescribed because of their good tolerability. Moreover, due to the results of the ONTARGET trial program, telmisartan was the first AT1 receptor antagonist to receive approval for the prevention of cardiovascular events in cardiovascular high risk patients, thereby, indicating that its clinical importance will further increase. AREAS COVERED IN THIS REVIEW: This article reviews the pharmacokinetic and pharmacodynamic properties of telmisartan with a special focus on novel pharmacokinetic characteristics of the drug. WHAT THE READER WILL GAIN: An overview of the published data regarding the pharmacokinetic properties of telmisartan as well as a summary of the results from selected small exploratory and large clinical outcome trials involving telmisartan. TAKE HOME MESSAGE: Telmisartan is a safe and effective alternative for the treatment of hypertension. Moreover, due to its good tolerability, an increasing use of telmisartan in cardiovascular high risk patients can be anticipated. This will grant further experimental and clinical research on AT1 receptor-independent pharmacodynamics of telmisartan as well as on telmisartan-related drug safety issues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20509777     DOI: 10.1517/17425255.2010.494597

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  19 in total

1.  Neurorestoration after traumatic brain injury through angiotensin II receptor blockage.

Authors:  Sonia Villapol; María G Balarezo; Kwame Affram; Juan M Saavedra; Aviva J Symes
Journal:  Brain       Date:  2015-06-26       Impact factor: 13.501

Review 2.  Telmisartan: a review of its use in cardiovascular disease prevention.

Authors:  James E Frampton
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

3.  Effects of UGT1A1 Polymorphism, Gender and Triglyceride on the Pharmacokinetics of Telmisartan in Chinese Patients with Hypertension: A Population Pharmacokinetic Analysis.

Authors:  Lu Huang; Liu Yang; Jie Huang; Hong-Yi Tan; Shi-Kun Liu; Cheng-Xian Guo; Xiao-Cong Zuo; Guo-Ping Yang; Qi Pei
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

4.  Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin.

Authors:  Miao Hu; Hon-Kit Lee; Kenneth K W To; Benny S P Fok; Siu-Kwan Wo; Chung-Shun Ho; Chun-Kwok Wong; Zhong Zuo; Thomas Y K Chan; Juliana C N Chan; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2016-09-20       Impact factor: 2.953

5.  The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1.

Authors:  Lasse Saaby; Peer Tfelt-Hansen; Birger Brodin
Journal:  Pharmacol Res Perspect       Date:  2015-06-11

Review 6.  Recent advances in developing small-molecule inhibitors against SARS-CoV-2.

Authors:  Rong Xiang; Zhengsen Yu; Yang Wang; Lili Wang; Shanshan Huo; Yanbai Li; Ruiying Liang; Qinghong Hao; Tianlei Ying; Yaning Gao; Fei Yu; Shibo Jiang
Journal:  Acta Pharm Sin B       Date:  2021-07-02       Impact factor: 14.903

7.  Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.

Authors:  Wang-Qing Chen; Yan Shu; Qing Li; Lin-Yong Xu; Mary W Roederer; Lan Fan; Lan-Xiang Wu; Fa-Zhong He; Jian-Quan Luo; Zhi-Rong Tan; Yi-Jing He; Hong-Hao Zhou; Xiang Chen; Wei Zhang
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

8.  Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers.

Authors:  Minkyung Oh; Sung-Eun Park; Jong-Lyul Ghim; Young-Kyung Choi; Eon-Jeong Shim; Jae-Gook Shin; Eun-Young Kim
Journal:  Drug Des Devel Ther       Date:  2017-12-11       Impact factor: 4.162

9.  Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter ABCG2.

Authors:  Anne Ripperger; Anna Krischer; Dina Robaa; Wolfgang Sippl; Ralf A Benndorf
Journal:  Front Pharmacol       Date:  2018-05-14       Impact factor: 5.810

10.  Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.

Authors:  E E J Kasteel; K Darney; N I Kramer; J L C M Dorne; L S Lautz
Journal:  Arch Toxicol       Date:  2020-05-15       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.